



Dr. Stephen Chia, MD, FRCP(C)

Stephen K. Chia, MD, FRCP (Canada), is an Associate Professor of Medicine in the Department of Medicine at the University of British Columbia, Vancouver, Canada. He also is a staff medical oncologist with the British Columbia Cancer Agency (BCCA), Vancouver Centre. Dr. Chia also serves as Chair for the British Columbia Breast Tumour Group, Chair of the BCCA Tumour Group Council, and is physician coordinator for both the breast cancer and head and neck cancer clinical trials at the BCCA – Vancouver Cancer Centre (VCC). He was also recently appointed a Subject Editor for the British Journal of Cancer.

Dr. Chia received his bachelor's degree in Pharmacology from the University of British Columbia, where he also earned his medical degree in 1993 and obtained his Internal Medicine Fellowship and Medical Oncology Fellowship. He then completed post-fellowship training from 1999 to 2000 with the Department of Advanced Therapeutics – British Cancer Research Centre and with the Institute of Molecular Medicine at the University of Oxford.

He is currently a member of the National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) Executive Committee, the NCIC CTG Breast Executive Committee, the NCIC IND Executive Committee, and the NCIC CTG Breast Correlative Science Committee. He is a past member of the American Society of Clinical Oncology (ASCO) Scientific Committee (2009 to 2012), ASCO Breast Symposium Committee (2014-2015) and served as a Breast Track chair (Triple Negative/Cytotoxic/Local) for the ASCO 2011 Annual Meeting. An active researcher in phase 1 to 3 trials in breast cancer and investigational new drugs, Dr. Chia has an established interest in neoadjuvant systemic therapy for breast cancer and drug development. He has spearheaded the efforts for the BCCA – VCC to be the first Canadian site for the I-SPY2 consortium. He is currently carrying out clinical and translational studies in breast cancer with peer-reviewed, grant-funded research from the NCIC, National Institutes of Health (USA), Canadian Breast Cancer Research Alliance, and Canadian Breast Cancer Foundation – British Columbia/Yukon Chapter.

Dr. Chia has been widely published (more than 85 peer-reviewed publications) in international peer-reviewed journals including The New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Journal of the National Cancer Institute, Cell, Annals of Oncology, and Clinical Cancer Research. Recently he has written the Commentaries in Lancet and Lancet Oncology for the latest EBCTCG Overview (2011), NOAH study (2010), GEPARQUINTO study (2012), and the BOLERO-3 study (2014) respectively.

Dr. Chia has been overall study PI on a large phase III clinical trial (EFFECT) as well as being on academic steering committees (ASC) for various other phase II and III trials (ExteNET, TRY-PHAENA, MONALEESA-3, RxPONDER). He also sits on the correlative science committee for the ALTO/NeoALTO clinical trial. He closely collaborates with researchers at the BC Cancer Research Centre (more so with Dr. Samuel Aparicio and Dr. Francois Benard) and helped initiate the primary xenograft program in patients undergoing neoadjuvant chemotherapy at the BCCA (Eirew P, et al. Nature 2014) and was involved in the study of the sequencing of primary triple negative breast cancers (Shah S, et al. Nature 2012). Dr. Chia has also led studies with the prognostic/predictive assays of PAM50 and Oncotype DX in primary breast cancers (Chia S, et al. Clin Cancer Res 2012; Chia S, et al. Eur J Cancer 2013).



Dr. Karen Gelmon, MD

Dr. Gelmon is a Professor of Medicine at the UBC and a Medical Oncologist at the BCCA, combining clinical and translational research. She is currently Head of the Division of Medical Oncology at the UBC. She is Co Chair of the Breast Site Committee for the NCIC Trials Group and a member of the NCI Breast Steering Committee and was a member of the BIG (Breast International Group) Advisory Group. She sits on the NCIC-CTG executive and is a past Chair of this committee. She is also a Komen scholar and member of the Scientific Advisory Council for Komen and Co Chair of the Scientific Advisory Council of the Ontario Institute of Cancer Research. She is Clinical leader of Advanced Therapeutics department at the BCCA. She sits on the International Advisory Board of The Lancet, The Oncologist and Clinical Breast Cancer. She is a reviewer for journals and grant review panels. She has been track teacher interested in education of health care professionals and the public and has published extensively. She has been a member of the Board of the BC Cancer Foundation, on the Medical Advisory Board of the BC/Yukon Chapter of the Canadian Breast Cancer Foundation and sits on the board of Rethink Breast Cancer. She was the recipient of the YWCA Woman of Distinction award in 2003 and an humanitarian award in 2011. She is the mother of two daughters and is active on volunteer boards for the arts and community in Vancouver.



Dr. Ivo Olivotto, MD

Dr. Olivotto is Professor and Head of the Division of Radiation Oncology and Developmental Radiotherapeutics at the University of British Columbia and VP of Radiation Therapy and Functional Imaging for the BC Cancer Agency. His clinical practice and research career have focused on improving care and treatment for patients with breast cancer with a particular emphasis on outcomes evaluation, the impact of treatment guidelines and technical innovation. He founded the BC Cancer Agency's Breast Cancer Outcomes Unit and has had a leadership role provincially and nationally in clinical trials evaluating the role of radiation therapy in breast cancer. Since September 2013, Dr. Olivotto moved to University of Calgary as the Head of Radiation Oncology at the Tom Baker Cancer Center.



Dr. Hope Rugo, MD

Dr. Rugo is Professor of Medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF), Helen Diller Family Comprehensive Cancer Center, where she directs Breast Cancer and Clinical Trial Education. Her research interests include novel therapies for advanced breast cancer, immune modulation to restore chemotherapy sensitivity, evaluation of circulating cells as novel markers of response and resistance to therapy, neoadjuvant therapy, and supportive care.

She is an investigator in, the national multicenter ISPY2 trial, and is the principal investigator of a number of clinical trials. She is 1 of 3 recipients of a Komen Promise Award, receives funding from the Breast Cancer Research Foundation, and serves on a number of steering committees for national and international trials. Dr. Rugo is a member of the ALLIANCE Breast Core Committee and the Translational Breast Cancer Research Consortium, is the UCSF representative to the National Comprehensive Cancer Network Guidelines Committee, and serves on several committees for the American Society of Clinical Oncology. She has published many peer-reviewed papers and has given presentations on a variety of breast cancer and supportive care-related topics.

With a summa cum laude undergraduate degree from Tufts University, Dr. Rugo received her medical degree from the University of Pennsylvania School of Medicine and completed both a residency in internal medicine and fellowship in hematology and oncology at UCSF. In addition, she completed a 2-year postdoctoral fellowship in immunology at Stanford University. She received the Cancer Care Physician of the Year Award in 2010.



Dr. Eric Storm, M.D.

Eric A. Strom, M.D. FACR graduated from Northwestern University Medical School in 1982. He is Board Certified in Internal Medicine (Residency: University of Kentucky) 1985, and Radiation Oncology (Residency: UT M.D. Anderson Cancer Center) 1990. He has been on the faculty at UT M.D. Anderson since 1990 with a focus on radiotherapy for breast cancer and melanoma. He was the Medical Director of the Nellie B. Connally Breast Center, 1999-2012, and was promoted to Professor in 2006. He is the past co-chair of the RTOG Breast Committee and a Fellow of the American College of Radiology.



Dr. Tiffany Traina

Dr. Tiffany A. Traina is an Associate Attending Physician and Clinical Director of the Breast Medicine Service at Memorial Sloan Kettering. She serves as the Section Head of the Triple Negative Breast Cancer Clinical Research Program. She is also Assistant Professor of Medicine at Weill Cornell Medicine in New York City. Her research program centers on the development of therapies for patients with breast cancers, with a particular focus on Triple Negative Breast Cancer and the role of the androgen receptor in breast cancers. Dr. Traina serves on the ASCO Scientific Program Committee for the Triple Negative Breast Cancer/Cytotoxics/Local Therapy track as well and is a member of the Translational Breast Cancer Research Consortium Triple Negative Breast Cancer Working Group. In addition, Dr Traina is a member of the 2016-2017 ASCO Leadership Development Program. Her research efforts have earned her the Hally Yaccino Steiner Award from the Susan G. Komen Breast Cancer Foundation. She has received teaching awards from Memorial Sloan Kettering and Weill Cornell Medicine and the 2014 Hero Award from the Triple Negative Breast Cancer Foundation.



Dr. Shawna Willey, MD

Dr. Shawna Willey is a Professor of Clinical Surgery at Georgetown University and the Vice Chair for Clinical Affairs for the Department of Surgery at MedStar Georgetown University Hospital. She also serves as the Director of the MedStar Regional Breast Health Program. A native of Iowa, she received her MD from the University of Iowa and completed her residency in surgery at the George Washington University Medical Center where she served as the Director of the Breast Care Center. In 2002 she became the Chief of Breast Surgery at Georgetown University Hospital and the Director of the Betty Lou Ourisman Breast Health Center in the Lombardi Comprehensive Cancer Center. As an active researcher in the Lombardi Comprehensive Cancer Center, Dr. Willey is the principal investigator on many clinical trials with a focus on outcomes and quality of life. She is a nationally recognized breast surgeon and has conducted educational programs throughout the world, including in Europe, Africa, Asia and the Middle East. Dr. Willey is an active member of the American Society of Breast Surgeons and served as its president in 2008-2009.



Dr. Guiseppe Viale

Professor Viale is chairman of the Central Pathology Office and of the Biological Protocol Working Group of the International Breast Cancer Study Group and Lead Pathologist of the Breast International Group, Vice President for Europe of the Senologic International Society, and Member of the FFPE Working Group of the Breast International and NCI-sponsored breast cancer Cooperative Groups, of the Early Breast Cancer Trialists Collaborative Group Steering Committee, of the Pathology Sub-study Group of the Intergroup Exemestane Study, and Founding Member of the International Sentinel Node Society. He has been active in clinical and translational researches on breast carcinoma, with particular reference to the development of the axillary sentinel lymph node biopsy, to the identification of predictors of response to endocrine and cytotoxic therapies, to the clinical validation of gene expression signatures and to the biological and clinical effects of a deregulated Numb/Notch pathway. Professor Viale authored 276 articles in indexed international Journals and 36 chapters in books. Giuseppe Viale, MD, FRCPath Professor of Pathology and Chairman, University of Milan School of Medicine Director of the Department of Pathology and Laboratory Medicine, European Institute of Oncology in Milan.



Dr. Robin Wilson, MD

Dr. Robin Wilson is a consultant specialist breast radiologist with twenty-six years experience working in the NHS in the UK. All of his clinical time is spent in the field of breast disease diagnosis, including mammography, breast ultrasound and breast MRI. He has particular expertise in breast screening, diagnostic breast imaging and interventional breast biopsy procedures.

Positions held:

- Consultant Radiologist, The Royal Marsden NHS Foundation Trust (previously Consultant Radiologist and Clinical Director of Breast Services, Nottingham Breast Institute (1988-2006) and King's College Hospital and Guy's and St Thomas' Hospitals NHS Foundation Trusts, London (2007-2009)
- Director, Nottingham Breast Institute 2003-2007.
- President, European Society of Breast Cancer Specialists (EUSOMA) 2012-2014
- Chairman, the British Society of Breast Radiology (2013 to present).
- Chairman, Department of Health (England) Breast Screening Advisory Committee (2012 to present)
- Member and former Chairman, National Health Service Breast Screening Programme Radiology Coordinating Committee (2002 – 2011)
- Faculty member and past President, International School of Breast Ultrasound (IBUS)
- Member, The British Breast Group.
- Member, National Institute for Health and Clinical Excellence (NICE) early breast cancer guidelines expert group (2008-2010).
- Director of Breast Screening Quality Assurance, East Midlands Region (2000 to 2006)

He is author or co-author of more than one hundred and seventy publications on breast imaging, including peer reviewed scientific papers, books, book chapters and UK NHS and European clinical guidelines on breast diagnosis and breast screening. He is currently a member of the research advisory committees for several current UK national breast related clinical trials